Previous 10 | Next 10 |
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actiona...
Centogene N.V. (CNTG) Q3 2020 Earnings Conference Call December 16, 2020 08:30 ET Company Participants Sun Kim - Investor Relations Richard Stoffelen - Chief Financial Officer Andrin Oswald - Chief Executive Officer Conference Call Participants Puneet Souda - SVB Leerink Sung Ji Nam - BTIG Ca...
The following slide deck was published by Centogene N.V. in conjunction with their 2020 Q3 earnings call. For further details see: Centogene N.V. 2020 Q3 - Results - Earnings Call Presentation
Centogene (CNTG) reports Q3 results:Revenues increased 212% Y/Y to €36.3M, driven by the continued expansion of our COVID-19 testing offering.Pharma revenues decreased 21%, while Clinical Diagnostics revenues (excl. COVID) decreased 25% compared to Q3 2019.Commercial COVID-19...
Centogene (CNTG): Q3 comprehensive loss of €5.7M.Revenue of €36.3M (+211.9% Y/Y)Shares +7% PM.Press Release For further details see: Centogene reports Q3 results
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actiona...
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutic...
Centogene N.V. (NASDAQ: CNTG) teams up with Alnylam Pharmaceuticals (NASDAQ:ALNY) to launch a new joint clinically screening program targeting the at-risk population for hereditary TransthyRetin-related Amyloidosis (ATTRv).In addition to the genetic screening of the patients, the study w...
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN and MUNICH, Germany, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicia...
Centogene N.V. (CNTG) has expanded its partnership with PTC Therapeutics (PTCT). The companies will work together to provide genetic testing and 3-O-Methyldopa (3-OMD) biomarker analytics to help identify patients with Aromatic L-amino Acid Decarboxylase ((AADC)) deficiency, a rare genet...
News, Short Squeeze, Breakout and More Instantly...
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answer...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company ...
CXApp Inc. (CXAI) is expected to report for quarter end 2024-03-31 Purple Biotech Ltd. (PPBT) is expected to report $-0.15 for Q1 2024 AutoZone Inc. (AZO) is expected to report $35.72 for Q3 2024 Turkcell Iletisim Hizmetleri AS (TKC) is expected to report for Q1 2024 Orkla ASA ADR...